호산구성 제2형 천식에서 혈액 백혈구 프로파일링: 전신 IL-5 표적화의 영향
The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Asthma is a chronic inflammatory and obstructive condition affecting the airways. The disease is commonly associated with elevated blood eosinophils and tissue eosinophilia. Many aspects of the pathophysiological mechanisms and clinical symptoms are controlled by conventional therapies such as inhaled corticosteroids (ICS) and long acting β2 agonists. However, some patients remain clinically uncontrolled and need additional treatment such as direct targeting of eosinophil granulocytes by neutralizing the eosinophil-promoting cytokine interleukin 5 (IL5). Mepolizumab is a humanized monoclonal IL-5 neutralizing antibody that is used to treat patients with moderate-severe eosinophilic asthma. While a marked reduction of eosinophils is a key effect of mepolizumab, the exact mechanism of action is unknown. Apart from basophils, that also express the receptor for IL-5, other leukocytes are likely to be indirectly affected by the suppressed eosinophilia. In addition, it is largely unknown to what extent the few eosinophils remaining after anti-IL5 treatment differ from pre-treatment eosinophils.
The present study is a prospective observational asthma study that aims to use microscopic analysis to investigate the composition and subtypes of blood leukocytes collected before and after instantiated mepolizumab treatment. Comparisons are made to patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
Skåne County
-
Lund, Skåne County, 스웨덴, 22185
- The Lung and Allergy Clinic, Skåne University Hospital (SUS)
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
All asthma patients will be recruited at the Department of Allergology and Lung Medicine, Skåne University Hospital (SUS), Lund, Sweden. Healthy control subjects are recruited by local advertisement.
설명
Inclusion Criteria:
- Clinical diagnosis of asthma (the asthma patient arms)
- Eligible for Mepolizumab treatment as per the country-specific prescribing information (the arms with Mepolizumab)
Exclusion criteria:
- Any diagnosed infection (all arms)
- Previous history of lung disease, chronic inflammatory condition, atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling (Healthy non-asthma control subjects)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: CROSS_SECTIONAL
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Asthma patients initiating Mepolizumab treatment
Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection |
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
다른 이름들:
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
다른 이름들:
|
|
Asthma patients already on Mepolizumab treatment
Patients that have been selected and given Mepolizumab treatment for > 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for > 4 weeks will be included. Exclusion criteria: any infections |
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
다른 이름들:
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
다른 이름들:
|
|
Asthma patients without Mepolizumab treatment
Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections |
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
다른 이름들:
|
|
Healthy non-asthmatic control subjects
Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Blood Eosinophil Marker Expression
기간: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood Basophil Marker Expression
기간: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections. |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood Leukocyte Composition
기간: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Blood T Lymphocyte Marker Expression
기간: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio). |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood B Lymphocyte Marker Expression
기간: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population. |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Leukocyte Total Cell Counts
기간: Baseline, Day 2, and Month 4 after mepolizumab initiation.
|
Routine clinical laboratory total leukocyte counts in peripheral blood |
Baseline, Day 2, and Month 4 after mepolizumab initiation.
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Forced Expiratory Volume in 1 Second (FEV1)
기간: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
Spirometry: Forced Expiratory Volume, 1s; (FEV1). |
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
|
Change in Forced Vital Capacity (FVC)
기간: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
Spirometry: Forced Vital Capacity (FVC) |
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
|
Change in Exhaled FeNo
기간: Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
|
Fractional exhaled NO will be measured at multiple flows |
Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Jonas Erjefält, Lund University Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- 1072615
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .